Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 14/20 | 0.57 |
| ▸ | CTSD | P07339 | 3/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31104091 | 0.90 | REN (0.58) | RENNTSR2NTSR1SORT1 | |
| SCHEMBL29665238 | 0.89 | REN (0.53) | RENNTSR2NTSR1SORT1 | |
| SCHEMBL29558594 | 0.88 | GHSR (0.56) | REN | |
| SCHEMBL30051269 | 0.88 | REN (0.60) | REN | |
| SCHEMBL29416073 | 0.87 | KDM1A (0.57) | REN | |
| SCHEMBL29615549 | 0.87 | REN (0.51) | RENCTSKNTSR2NTSR1SORT1 | |
| SCHEMBL30038268 | 0.86 | CALCRL (0.56) | REN | |
| SCHEMBL30733440 | 0.85 | REN (0.64) | REN | |
| SCHEMBL31442161 | 0.85 | EDNRA (0.51) | REN | |
| SCHEMBL8953885 | 0.84 | CALCRL (0.56) | RENCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376497-A1 | ARTIFICIAL PROTEIN AND USES THEREOF | ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA (IT) | 2025-12-11 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250326866-A1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDE OLIGONUCLEOTIDE COMPLEXES AND METHODS OF USE THEREOF | BLAZE BIOSCIENCE INC (US) | 2025-10-23 | — | — | US | claimed |
| EP-4547707-A1 | ARTIFICIAL PROTEIN AND USES THEREOF | Alma Mater Studiorum - Università di Bologna (IT) | 2025-05-07 | — | — | EP | claimed |
| CN-119708135-A | ASAP1/ASAP2 targeting polypeptide and application thereof | 深圳湾实验室 | 2025-03-28 | — | — | CN | claimed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| CN-118388663-A | Targeted fusion peptide for inhibiting COL11A1 nuclear transfer | 盐城三叶全生生物科技有限公司 | 2024-07-26 | — | — | CN | claimed |
| WO-2024003128-A1 | ARTIFICIAL PROTEIN AND USES THEREOF | ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA (IT) | 2024-01-04 | — | — | WO | claimed |
| CN-116178569-A | Targeted fusion peptide for inhibiting nuclear transport of NR5A2 and application thereof | 盐城市第三人民医院 | 2023-05-30 | — | — | CN | claimed |
| CN-115947863-A | Targeted fusion peptide for inhibiting nuclear transport of CPB1 and application | 江苏医药职业学院 | 2023-04-11 | — | — | CN | claimed |
| US-20230066474-A1 | LYSOSOME-TARGETING ANTIBODY-DRUG CONJUGATE AND USE THEREOF | SUN YAT-SEN UNIVERSITY (CN) | 2023-03-02 | — | — | US | claimed |
| WO-2023023031-A2 | TRANSFERRIN RECEPTOR TARGETING PEPTIDE OLIGONUCLEOTIDE COMPLEXES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2023-02-23 | — | — | WO | claimed |
| EP-4043034-A9 | LYSOSOME-TARGETING ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | Sun Yat-Sen University (CN) | 2023-01-25 | — | — | EP | claimed |
| US-11548923-B2 | Peptide compositions and methods of use thereof for disrupting TEAD interactions | FRED HUTCHINSON CANCER CENTER (US) | 2023-01-10 | — | — | US | claimed |
| EP-4061393-A1 | METHOD FOR THE DEVELOPMENT OF A DELIVERY PLATFORM TO PRODUCE DELIVERABLE PTD-IVT-MRNA THERAPEUTICS | Aristotle University of Thessaloniki - Elke (GR) | 2022-09-28 | — | — | EP | claimed |
| EP-4043034-A1 | LYSOSOME-TARGETING ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | Sun Yat-Sen University (CN) | 2022-08-17 | — | — | EP | claimed |
| CN-114478804-A | Fusion peptide targeting pancreatic cancer and application | 江苏医药职业学院 | 2022-05-13 | — | — | CN | claimed |
| CN-114316014-A | Leader peptide for targeted inhibition of neuroblastoma cell growth, fusion peptide and application thereof | 江苏医药职业学院 | 2022-04-12 | — | — | CN | claimed |
| CN-114262698-A | Leader peptide for targeted inhibition of MSI colorectal cancer cell growth, fusion peptide and application thereof | 江苏医药职业学院 | 2022-04-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230066474-A1 | LYSOSOME-TARGETING ANTIBODY-DRUG CONJUGATE AND USE THEREOF | LAMP2, LAMP1, DNM2 | REN 1784/4885CTSD 102/4885CTSB 30/4885 |
| US-20250326866-A1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDE OLIGONUCLEOTIDE COMPLEXES AND METHODS OF USE THEREOF | TFRC, TEK, FOLR1 | REN 3365/4885CTSD 1438/4885CTSB 1142/4885 |
| US-11548923-B2 | Peptide compositions and methods of use thereof for disrupting TEAD interactions | MST1, YAP1, KRAS | REN 1349/4885CTSD 844/4885CTSB 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.